Content intended for healthcare professionals. By continuing, you confirm you are a HCP.
TBS · DXA
CE · FDA
The global standard for osteoporosis fracture-risk assessment
The global standard for osteoporosis fracture-risk assessment. TBS Osteo™ adds bone-microarchitecture analysis to your routine DXA scan — no extra radiation, no workflow disruption.
Overview
See fracture risk more clearly
While DXA measures BMD — an important indicator of fracture risk — it doesn't capture the full picture. Bone microarchitecture, the internal structure of bone, is an independent determinant of bone strength and helps identify patients who would otherwise be missed.
Adding TBS® to DXA via TBS Osteo™ can help identify up to 30% of patients at risk of fracture classified as osteopenic by BMD alone.1
Osteopenic bone density
TBS® reveals the fracture risk BMD alone can miss
Benefits
Get more from your DXA
While DXA measures BMD, an important indicator of fracture risk, it doesn’t capture the full picture.
Clinical confidence
Beyond bone density
TBS Osteo™ improves fracture-risk assessment beyond BMD to support more confident decisions, especially in normal or osteopenic BMD and secondary osteoporosis
Seamless integration
No new workflow
Fully integrated TBS® Osteo reporting across connected DXA systems — no added scan time or radiation — and results are sent to PACS as a DICOM structured report
Economic value
Reimbursed care
TBS Osteo™ supports institutional value through referrals and reimbursement alignment under four dedicated CPT® codes in the US, billable alongside DXA
How it works
Bone insights within seconds
1
Standard DXA scan
TBS Osteo™ analyses routine spine BMD images. No additional scan or radiation required.
2
Automatic TBS analysis
TBS® is computed automatically from the DXA image to assess trabecular bone microarchitecture.
3
Instant structured report
An easy-to-interpret, editable report combining BMD, FRAX® and TBS®, delivered to your PACS.
US reimbursement
Reimbursed under four dedicated CPT® codes
TBS Osteo™ is reimbursed in the US and can be billed alongside DXA when ordered by a referring or treating physician.
Coverage may vary by payer, plan, and region.
77089
77090
77091
77092
Clinically proven
Worldwide clinical evidence
4.5M+
TBS® evaluations performed annually7
1,600+
peer-reviewed publications7
35+
clinical guidelines citing TBS®8
90+
countries with clinical deployments7
Clinically proven
TBS evidence keeps growing
2026 · Archives of Osteoporosis
The Effects of Spaceflight Countermeasures on Trabecular Bone Score (TBS) of the Lumbar Spine
Anderson, K.D., Spector, E.R., et al.
2026 · Transplantation
Kratochvílová, S., Brunová, J., et al.
2026 · Diagnostics
Razvan, D.V., Rosca, O., et al.
Resources
Explore TBS Osteo
TBS Osteo brochure
Explore how TBS Osteo™ adds TBS® to standard DXA scans, delivering a clearer picture of bone
TBS white paper
Explore the scientific basis, clinical utility, and value of TBS® in osteoporosis management
TBS Osteo report
Preview the report that supports timely and confident assessment of bone fragility
TBS in clinical practice
Learn how TBS® is used in clinical practice for fracture risk prediction (ESCEO-IOF, 2023)
Hardware partners
Runs on the DXA systems you already own
TBS Osteo™ integrates into leading DXA platforms, no new hardware required. Compatible with GE HealthCare, Hologic, and OsteoSys DXA systems.
Book a demo
See TBS Osteo in action
Tell us a little about your setting and our clinical team will be in touch to arrange a personalised walkthrough.
Please don't include patient information (PHI). We'll respond within two business days.
TBS Osteo™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Osteo is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). TBS Osteo is FDA 510(k) cleared (K243218) for use in the United States. TBS Osteo is included on the Australian Register of Therapeutic Goods (ARTG No. 528950) as "Inovanz Pty Ltd — X-ray system, diagnostic, general-purpose, application program software". Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.
References (3)
1. Hans, D., Goertzen, A.L., Krieg, M.-A. and Leslie, W. D (2011). Bone Microarchitecture Assessed by TBS Predicts Osteoporotic Fractures Independent of Bone Density: The Manitoba Study. Journal of Bone and Mineral Research, 26(11), pp.2762–2769. doi:10.1002/jbmr.499.
2. Enisa Shevroja, Jean-Yves Reginster, Lamy, O., Al-Daghri, N.M., Chandran, M., Anne-Laurence Demoux, Kohlmeier, L., Marie-Paule Lecart, Osvaldo Daniel Messina, Bruno Muzzi Camargos, Payer, J., Sansin Tuzun, Veronese, N., Cooper, C., McCloskey, E. and Harvey, N.C. (2023). Update on the Clinical Use of Trabecular Bone Score (TBS) in the Management of Osteoporosis: Results of an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) Under the Auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporosis International, 34(9), pp.1501–1529. doi:10.1007/s00198-023-06817-4.
3. Medimaps Group (2026) Internal data (data on file).